nogrЭкспериментальная и клиническая гастроэнтерологияExperimental and Clinical Gastroenterology1682-8658«Global Media Technologies»10.31146/1682-8658-ecg-215-7-25-33nogr-2521Research ArticleКЛИНИЧЕСКАЯ ГАСТРОЭНТЕРОЛОГИЯCLINICAL GASTROENTEROLOGYКишечная микробиота у детей при аутоиммунных и неаутоиммунных заболеваниях печениGut microbiota in autoimmune and non-autoimmune liver diseases in childrenhttps://orcid.org/0000-0002-5413-9599ВолынецГ. В.VolynetsG. V.volynec_g@mail.ruhttps://orcid.org/0000-0001-8837-9243НикитинА. В.NikitinA. V.noemail@neicon.ruhttps://orcid.org/0000-0002-6525-8665СкворцоваТ. А.SkvortsovaT. A.noemail@neicon.ruhttps://orcid.org/0000-0003-4905-2373ПотаповА. С.PotapovA. S.noemail@neicon.ruhttps://orcid.org/0000-0002-6271-5218ДудуричВ. В.DudurichV. V.noemail@neicon.ruhttps://orcid.org/0000-0002-4479-3095ДаниловЛ. Г.DanilovL. G.noemail@neicon.ruКокиашвилиВ. С.KokiashviliV. S.noemail@neicon.ruФедеральное государственное автономное образовательное учреждение высшего образования «Российский национальный исследовательский медицинский университет имени Н. И. Пирогова» Министерства здравоохранения Российской ФедерацииРоссияPirogov Russian National Research Medical UniversityRussian FederationФедеральное государственное автономное образовательное учреждение высшего образования «Российский национальный исследовательский медицинский университет имени Н. И. Пирогова» Министерства здравоохранения Российской Федерации; Государственное бюджетное учреждение здравоохранения города Москвы «Морозовская детская городская клиническая больница Департамента здравоохранения города Москвы»РоссияPirogov Russian National Research Medical University; Morozov Children’s City Clinical Hospital of the Moscow City Healthcare DepartmentRussian FederationФедеральное государственное автономное учреждение «Национальный медицинский исследовательский центр здоровья детей» Министерства здравоохранения Российской ФедерацииРоссияNational Medical Research Center for Children’s HealthRussian FederationМедико-генетический центр “CERBALAB”РоссияMedical Genetic Center “CERBALAB”Russian FederationМедико-генетический центр “CERBALAB”; Федеральное государственное бюджетное образовательное учреждение высшего образования «Санкт-Петербургский государственный университет»РоссияMedical Genetic Center “CERBALAB”; St Petersburg UniversityRussian Federation202307032024072533Copyright © Волынец Г.В., Никитин А.В., Скворцова Т.А., Потапов А.С., Дудурич В.В., Данилов Л.Г., Кокиашвили В.С., 20242024Волынец Г.В., Никитин А.В., Скворцова Т.А., Потапов А.С., Дудурич В.В., Данилов Л.Г., Кокиашвили В.С.Volynets G.V., Nikitin A.V., Skvortsova T.A., Potapov A.S., Dudurich V.V., Danilov L.G., Kokiashvili V.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.nogr.org/jour/article/view/2521

Актуальность. Влияние кишечной микробиоты на развитие различных заболеваний вызывает огромный интерес исследователей. Проведённые исследования показали, что у пациентов с хроническими заболеваниями печени доминирующими таксонами кишечной микробиоты были Bifidobacterium longum, Bifidobacterium adolescentis, Blautia massiliensis а у здоровых детей - Neisseria flavescens. Сравнительный анализ данных о таксономическом разнообразии кишечной микробиоты при аутоиммунных и неаутоиммунных заболеваниях печени у детей отсутствует. Цель. Исследовать различия в таксономическом разнообразии фекальной микробиоты у пациентов с аутоиммунными и неаутоиммунными заболеваниями печени, а также оценке потенциальных биомаркеров ампликонов гена 16S рРНК при этих заболеваниях путем сравнения таксономического состава. Объём и методы исследования. Проведён метагеномный анализ кишечной микробиоты 24 детей с хроническими заболеваниями печени (средний возраст 10,3±4,7 лет) с выделением региона V3-V4 гена 16S рРНК. В группу вошли 18 детей с аутоиммунными заболеваниями печени и 6 детей с неаутоиммунными заболеваниями печени. Результаты исследования. Проведённое исследование выявило 684 вида микроорганизмов в исследуемых образцах фекалий пациентов. Анализ проведённых исследований показал, что в образцах фекалий детей с аутоиммунными заболеваниями печени доминирующих таксонов не выявлено, а у пациентов с неаутоиммунными заболеваниями печени доминирующим таксонами были Veillonella dispar, Veillonella parvula, Cloacibacillus porcorum, Prevotella histicola и Bacteroides eggerthii. Заключение. Проведённые исследования показали различия в составе кишечной микробиоты у детей с аутоиммунными и неаутоиммунными заболеваниями печени.

Relevance. The influence of the gut microbiota on the development of various diseases is of great interest to researchers. The conducted studies showed that in patients with chronic liver diseases, the dominant taxa of the gut microbiota were Bifidobacterium longum, Bifidobacterium adolescentis, Blautia massiliensis, and in healthy children - Neisseria flavescens. There is no comparative analysis of data on the taxonomic diversity of the intestinal microbiota in autoimmune and non-autoimmune liver diseases in children. Purpose of the study. To investigate differences in the taxonomic diversity of fecal microbiota in patients with autoimmune and non-autoimmune liver diseases, as well as to evaluate potential biomarkers of 16S rRNA gene amplicons in these diseases by comparing the taxonomic composition. Scope and methods of research. A metagenomic analysis of the intestinal microbiota of 24 children with chronic liver diseases (mean age 10.3±4.7 years) was carried out with the identification of the V3-V4 region of the 16S rRNA gene. The group included 18 children with autoimmune liver diseases and 6 children with non-autoimmune liver diseases. Research results. The conducted study revealed 684 types of microorganisms in the studied samples of patients’ faeces. The analysis of the conducted studies showed that no dominant taxa were found in the faecal samples of children with autoimmune liver diseases, while Veillonella dispar, Veillonella parvula, Cloacibacillus porcorum, Prevotella histicola and Bacteroides eggerthii were the dominant taxa in patients with non-autoimmune liver diseases. Conclusion. Studies have shown differences in the composition of the gut microbiota in children with autoimmune and non-autoimmune liver diseases.

кишечная микробиотадетиаутоиммунные болезни печенинеаутоиммунные болезни печениgut microbiotachildrenautoimmune liver diseasesnon-autoimmune liver diseasesReferencesHe Y., Wu W., Zheng H. M., Li P., McDonald D., Sheng H. F. et al. Regional variation limits applications of healthy gut microbiome reference ranges and disease models. Nat Med. 2018; 24(10): 1532-1535. doi: 10.1038/s41591-018-0164-x.He Y., Wu W., Zheng H. M., Li P., McDonald D., Sheng H. F. et al. Regional variation limits applications of healthy gut microbiome reference ranges and disease models. Nat Med. 2018; 24(10): 1532-1535. doi: 10.1038/s41591-018-0164-x.Huttenhower C., Gevers D., Knight R., Abubucker S., Badger JH., Chinwalla AT. et al. Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature. 2012; 486(7402): 207-14. doi: 10.1038/nature11234.Huttenhower C., Gevers D., Knight R., Abubucker S., Badger JH., Chinwalla AT. et al. Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature. 2012; 486(7402): 207-14. doi: 10.1038/nature11234.David L.A., Maurice C. F., Carmody R. N. et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature. 2014; 505(7484): 559-63. doi: 10.1038/nature12820.David L.A., Maurice C. F., Carmody R. N. et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature. 2014; 505(7484): 559-63. doi: 10.1038/nature12820.Sonnenburg E.D., Smits S. A., Tikhonov M., Higginbottom S. K., Wingreen N. S., Sonnenburg J. L. Diet-induced extinctions in the gut microbiota compound over generations. Nature. 2016; 529(7585): 212-5. doi: 10.1038/nature16504.Sonnenburg E.D., Smits S. A., Tikhonov M., Higginbottom S. K., Wingreen N. S., Sonnenburg J. L. Diet-induced extinctions in the gut microbiota compound over generations. Nature. 2016; 529(7585): 212-5. doi: 10.1038/nature16504.Modi S.R., Collins J. J., Relman D. A. Antibiotics and the gut microbiota. Clin Invest. 2014; 124(10): 4212-8. doi: 10.1172/JCI72333.Modi S.R., Collins J. J., Relman D. A. Antibiotics and the gut microbiota. Clin Invest. 2014; 124(10): 4212-8. doi: 10.1172/JCI72333.Maurice C.F., Haiser H. J., Turnbaugh P. J. Xenobiotics shape the physiology and gene expression of the active human gut microbiome. Cell. 2013; 152(1-2): 39-50. doi: 10.1016/j.cell.2012.10.052.Maurice C.F., Haiser H. J., Turnbaugh P. J. Xenobiotics shape the physiology and gene expression of the active human gut microbiome. Cell. 2013; 152(1-2): 39-50. doi: 10.1016/j.cell.2012.10.052.Sonnenburg J.L., Backhed F. Diet-microbiota interactions as moderators of human metabolism. Nature. 2016; 535(7610): 56-64. doi: 10.1038/nature18846.Sonnenburg J.L., Backhed F. Diet-microbiota interactions as moderators of human metabolism. Nature. 2016; 535(7610): 56-64. doi: 10.1038/nature18846.Jones R.M., Neish A. S. Gut Microbiota in Intestinal and Liver Disease. Annu Rev Pathol. 2021;.16:251-275. doi: 10.1146/annurev-pathol-030320-095722.Jones R.M., Neish A. S. Gut Microbiota in Intestinal and Liver Disease. Annu Rev Pathol. 2021;.16:251-275. doi: 10.1146/annurev-pathol-030320-095722.Xu X.R., Liu C. Q., Feng B. S., Liu Z. J. Dysregulation of mucosal immune response in pathogenesis of inflammatory bowel disease. World J Gastroenterol. 2014; 20(12): 3255-64. doi: 10.3748/wjg.v20.i12.3255.Xu X.R., Liu C. Q., Feng B. S., Liu Z. J. Dysregulation of mucosal immune response in pathogenesis of inflammatory bowel disease. World J Gastroenterol. 2014; 20(12): 3255-64. doi: 10.3748/wjg.v20.i12.3255.Carrière J., Darfeuille-Michaud A., Nguyen HT. Infectious etiopathogenesis of Crohn’s disease. World J Gastroenterol. 2014; 20(34): 12102-17. doi: 10.3748/wjg.v20.i34.12102.Carrière J., Darfeuille-Michaud A., Nguyen HT. Infectious etiopathogenesis of Crohn’s disease. World J Gastroenterol. 2014; 20(34): 12102-17. doi: 10.3748/wjg.v20.i34.12102.Abraham C., Cho J. H. Inflammatory bowel disease. N Engl J Med. 2009; 361(21): 2066-78. doi: 10.1056/NEJMra0804647.Abraham C., Cho J. H. Inflammatory bowel disease. N Engl J Med. 2009; 361(21): 2066-78. doi: 10.1056/NEJMra0804647.Kaser A., Zeissig S., Blumberg R. S. Inflammatory bowel disease. Annu Rev Immunol. 2010; 28: 573-621. doi: 10.1146/annurev-immunol-030409-101225.Kaser A., Zeissig S., Blumberg R. S. Inflammatory bowel disease. Annu Rev Immunol. 2010; 28: 573-621. doi: 10.1146/annurev-immunol-030409-101225.Adolph T.E., Grander C., Moschen A. R., Tilg H. Liver-Microbiome Axis in Health and Disease. Trends Immunol. 2018; 39(9): 712-723. doi: 10.1016/j.it.2018.05.002.Adolph T.E., Grander C., Moschen A. R., Tilg H. Liver-Microbiome Axis in Health and Disease. Trends Immunol. 2018; 39(9): 712-723. doi: 10.1016/j.it.2018.05.002.Kummen M., Holm K., Anmarkrud J. A., Nygård S., Vesterhus M., Høivik M.L, et al. The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls. Gut. 2017; 66(4): 611-619. doi: 10.1136/gutjnl-2015-310500.Kummen M., Holm K., Anmarkrud J. A., Nygård S., Vesterhus M., Høivik M.L, et al. The gut microbial profile in patients with primary sclerosing cholangitis is distinct from patients with ulcerative colitis without biliary disease and healthy controls. Gut. 2017; 66(4): 611-619. doi: 10.1136/gutjnl-2015-310500.Sabino J., Vieira-Silva S., Machiels K., Joossens M., Falony G., Ballet V. et al. Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD. Gut. 2016; 65(10): 1681-9. doi: 10.1136/gutjnl-2015-311004.Sabino J., Vieira-Silva S., Machiels K., Joossens M., Falony G., Ballet V. et al. Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD. Gut. 2016; 65(10): 1681-9. doi: 10.1136/gutjnl-2015-311004.Tang R., Wei Y., Li Y., Chen W., Chen H., Wang Q. et al. Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy. Gut. 2018; 67(3): 534-541. doi: 10.1136/gutjnl-2016-313332.Tang R., Wei Y., Li Y., Chen W., Chen H., Wang Q. et al. Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy. Gut. 2018; 67(3): 534-541. doi: 10.1136/gutjnl-2016-313332.Tripathi A., Debelius J., Brenner D. A., Karin M., Loomba R., Schnabl B. et al. The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol. 2018; 15(7): 397-411. doi: 10.1038/s41575-018-0011-z.Tripathi A., Debelius J., Brenner D. A., Karin M., Loomba R., Schnabl B. et al. The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol. 2018; 15(7): 397-411. doi: 10.1038/s41575-018-0011-z.Manfredo Vieira S., Hiltensperger M., Kumar V., Zegarra-Ruiz D., Dehner C., Khan N. et al. Translocation of a gut pathobiont drives autoimmunity in mice and humans. Science. 2018; 359(6380): 1156-1161. doi: 10.1126/science.aar7201.Manfredo Vieira S., Hiltensperger M., Kumar V., Zegarra-Ruiz D., Dehner C., Khan N. et al. Translocation of a gut pathobiont drives autoimmunity in mice and humans. Science. 2018; 359(6380): 1156-1161. doi: 10.1126/science.aar7201.Yuksel M., Wang Y., Tai N., Peng J., Guo J., Beland K. et al. A novel “humanized mouse” model for autoimmune hepatitis and the association of gut microbiota with liver inflammation. Hepatology. 2015; 62(5): 1536-50. doi: 10.1002/hep.27998.Yuksel M., Wang Y., Tai N., Peng J., Guo J., Beland K. et al. A novel “humanized mouse” model for autoimmune hepatitis and the association of gut microbiota with liver inflammation. Hepatology. 2015; 62(5): 1536-50. doi: 10.1002/hep.27998.Klaassen C.D., Cui J. Y. Review: mechanisms of how the intestinal microbiota alters the effects of drugs and bile acids. Drug Metab Dispos. 2015; 43(10): 1505-21. doi: 10.1124/dmd.115.065698.Klaassen C.D., Cui J. Y. Review: mechanisms of how the intestinal microbiota alters the effects of drugs and bile acids. Drug Metab Dispos. 2015; 43(10): 1505-21. doi: 10.1124/dmd.115.065698.Dawson P.A., Karpen S. J.Intestinal transport and metabolism of bile acids. J Lipid Res. 2015; 56(6): 1085-99. doi: 10.1194/jlr.R054114Dawson P.A., Karpen S. J.Intestinal transport and metabolism of bile acids. J Lipid Res. 2015; 56(6): 1085-99. doi: 10.1194/jlr.R054114Sayin S.I., Wahlström A., Felin J., Jäntti S., Marschall H. U., Bamberg K. et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab. 2013; 17(2): 225-35. doi: 10.1016/j.cmet.2013.01.003.Sayin S.I., Wahlström A., Felin J., Jäntti S., Marschall H. U., Bamberg K. et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab. 2013; 17(2): 225-35. doi: 10.1016/j.cmet.2013.01.003.Jia W., Xie G., Jia W. Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis. Nat Rev Gastroenterol Hepatol. 2018; 15(2): 111-128. doi: 10.1038/nrgastro.2017.119.Jia W., Xie G., Jia W. Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis. Nat Rev Gastroenterol Hepatol. 2018; 15(2): 111-128. doi: 10.1038/nrgastro.2017.119.Wahlström A., Sayin S. I., Marschall H. U., Bäckhed F.Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab. 2016; 24(1): 41-50. doi: 10.1016/j.cmet.2016.05.005.Wahlström A., Sayin S. I., Marschall H. U., Bäckhed F.Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab. 2016; 24(1): 41-50. doi: 10.1016/j.cmet.2016.05.005.Spadoni I., Zagato E., Bertocchi A., Paolinelli R., Hot E., Di Sabatino A. et al. A gut-vascular barrier controls the systemic dissemination of bacteria. Science. 2015; 350(6262): 830-4. doi: 10.1126/science.aad0135.Spadoni I., Zagato E., Bertocchi A., Paolinelli R., Hot E., Di Sabatino A. et al. A gut-vascular barrier controls the systemic dissemination of bacteria. Science. 2015; 350(6262): 830-4. doi: 10.1126/science.aad0135.Balmer M.L., Slack E., de Gottardi A., Lawson M. A., Hapfelmeier S., Miele L. et al. The liver may act as a firewall mediating mutualism between the host and its gut commensal microbiota. Sci Transl Med. 2014; 6(237): 237ra66. doi: 10.1126/scitranslmed.3008618.Balmer M.L., Slack E., de Gottardi A., Lawson M. A., Hapfelmeier S., Miele L. et al. The liver may act as a firewall mediating mutualism between the host and its gut commensal microbiota. Sci Transl Med. 2014; 6(237): 237ra66. doi: 10.1126/scitranslmed.3008618.Chen F., Stappenbeck T. S. Microbiome control of innate reactivity. Curr Opin Immunol. 2019; 56: 107-113. doi: 10.1016/j.coi.2018.12.003Chen F., Stappenbeck T. S. Microbiome control of innate reactivity. Curr Opin Immunol. 2019; 56: 107-113. doi: 10.1016/j.coi.2018.12.003Callahan B.J., McMurdie P.J., Rosen M. J., Han A. W., Johnson A. J., Holmes S. P. DADA2: High-resolution sample inference from Illumina amplicon data. Nat Methods. 2016; 13(7): 581-583. doi: 10.1038/nmeth.3869.Callahan B.J., McMurdie P.J., Rosen M. J., Han A. W., Johnson A. J., Holmes S. P. DADA2: High-resolution sample inference from Illumina amplicon data. Nat Methods. 2016; 13(7): 581-583. doi: 10.1038/nmeth.3869.Wang E.T., Moyzis R. K. Genetic evidence for ongoing balanced selection at human DNA repair genes ERCC8, FANCC, and RAD51C. Mutat Res. 2007; 616(1-2): 165-74. doi: 10.1016/j.mrfmmm.2006.11.030Wang E.T., Moyzis R. K. Genetic evidence for ongoing balanced selection at human DNA repair genes ERCC8, FANCC, and RAD51C. Mutat Res. 2007; 616(1-2): 165-74. doi: 10.1016/j.mrfmmm.2006.11.030Quast C., Pruesse E., Yilmaz P., Gerken J., Schweer T., Yarza P. et al. The SILVA ribosomal RNA gene database project: improved data processing and web-based tools. Nucleic Acids Res. 2013; 41(Database issue): D590-D596. DOI:10.1093/nar/gks1219Quast C., Pruesse E., Yilmaz P., Gerken J., Schweer T., Yarza P. et al. The SILVA ribosomal RNA gene database project: improved data processing and web-based tools. Nucleic Acids Res. 2013; 41(Database issue): D590-D596. DOI:10.1093/nar/gks1219Blander J.M., Longman R. S., Iliev I. D., Sonnenberg G. F., Artis D. Regulation of inflammation by microbiota interactions with the host. Nat Immunol. 2017; 18(8): 851-860. doi: 10.1038/ni.3780Blander J.M., Longman R. S., Iliev I. D., Sonnenberg G. F., Artis D. Regulation of inflammation by microbiota interactions with the host. Nat Immunol. 2017; 18(8): 851-860. doi: 10.1038/ni.3780Clemente J.C., Manasson J., Scher J. U. The role of the gut microbiome in systemic inflammatory disease. BMJ. 2018; 360: j5145. doi: 10.1136/bmj.j5145Clemente J.C., Manasson J., Scher J. U. The role of the gut microbiome in systemic inflammatory disease. BMJ. 2018; 360: j5145. doi: 10.1136/bmj.j5145Gevers D., Kugathasan S., Denson L. A., Vázquez-Baeza Y., Van Treuren W., Ren B. et al. The treatment-naive microbiome in new-onset Crohn’s disease. Cell Host Microbe. 2014; 15(3): 382-392. doi: 10.1016/j.chom.2014.02.005Gevers D., Kugathasan S., Denson L. A., Vázquez-Baeza Y., Van Treuren W., Ren B. et al. The treatment-naive microbiome in new-onset Crohn’s disease. Cell Host Microbe. 2014; 15(3): 382-392. doi: 10.1016/j.chom.2014.02.005Kummen M., Hov J. R. The gut microbial influence on cholestatic liver disease. Liver Int. 2019; 39(7): 1186-1196. doi: 10.1111/liv.14153Kummen M., Hov J. R. The gut microbial influence on cholestatic liver disease. Liver Int. 2019; 39(7): 1186-1196. doi: 10.1111/liv.14153Volynets G.V., Nikitin A. V., Skvortsova T. A., Potapov A. S., Dudurich V. V., Danilov L. G. Gut microbiota in chronic liver disease in children.Russian Bulletin of Perinatology and Pediatrics. 2023; 68(2): 69-73. (in Russ.) doi: 10.21508/1027-4065-2023-68-2-69-73.@@ Волынец Г. В., Никитин А. В., Скворцова Т. А., Потапов А. С., Дудурич В. В., Данилов Л. Г. Кишечная микробиота при хронических заболеваниях печени у детей. Российский вестник перинатологии и педиатрии. 2023; 68(2): 69-73. doi: 10.21508/1027-4065-2023-68-2-69-73.Volynets G.V., Nikitin A. V., Skvortsova T. A., Potapov A. S., Dudurich V. V., Danilov L. G. Gut microbiota in chronic liver disease in children.Russian Bulletin of Perinatology and Pediatrics. 2023; 68(2): 69-73. (in Russ.) doi: 10.21508/1027-4065-2023-68-2-69-73.@@ Волынец Г. В., Никитин А. В., Скворцова Т. А., Потапов А. С., Дудурич В. В., Данилов Л. Г. Кишечная микробиота при хронических заболеваниях печени у детей. Российский вестник перинатологии и педиатрии. 2023; 68(2): 69-73. doi: 10.21508/1027-4065-2023-68-2-69-73.Nakamoto N., Sasaki N., Aoki R., Miyamoto K., Suda W., Teratani T. et al. Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis. Nat Microbiol. 2019; 4(3): 492-503. doi: 10.1038/s41564-018-0333-1.Nakamoto N., Sasaki N., Aoki R., Miyamoto K., Suda W., Teratani T. et al. Gut pathobionts underlie intestinal barrier dysfunction and liver T helper 17 cell immune response in primary sclerosing cholangitis. Nat Microbiol. 2019; 4(3): 492-503. doi: 10.1038/s41564-018-0333-1.Liao L., Schneider K. M., Galvez E. J.C., Frissen M., Marschall H. U., Su H. et al.Intestinal dysbiosis augments liver disease progression via NLRP3 in a murine model of primary sclerosing cholangitis. Gut. 2019; 68(8): 1477-1492. doi: 10.1136/gutjnl-2018-316670.Liao L., Schneider K. M., Galvez E. J.C., Frissen M., Marschall H. U., Su H. et al.Intestinal dysbiosis augments liver disease progression via NLRP3 in a murine model of primary sclerosing cholangitis. Gut. 2019; 68(8): 1477-1492. doi: 10.1136/gutjnl-2018-316670.Zhao S., Gong Z., Zhou J., Tian C., Gao Y., Xu C. et al. Deoxycholic Acid Triggers NLRP3 Inflammasome Activation and Aggravates DSS-Induced Colitis in Mice. Front Immunol. 2016; 7:536. doi: 10.3389/fimmu.2016.00536.Zhao S., Gong Z., Zhou J., Tian C., Gao Y., Xu C. et al. Deoxycholic Acid Triggers NLRP3 Inflammasome Activation and Aggravates DSS-Induced Colitis in Mice. Front Immunol. 2016; 7:536. doi: 10.3389/fimmu.2016.00536.Deng X., Li Z., Li G., Li B., Jin X., Lyu G.Comparison of Microbiota in Patients Treated by Surgery or Chemotherapy by 16S rRNA Sequencing Reveals Potential Biomarkers for Colorectal Cancer Therapy. Front Microbiol. 2018; 9: 1607. doi: 10.3389/fmicb.2018.01607.Deng X., Li Z., Li G., Li B., Jin X., Lyu G.Comparison of Microbiota in Patients Treated by Surgery or Chemotherapy by 16S rRNA Sequencing Reveals Potential Biomarkers for Colorectal Cancer Therapy. Front Microbiol. 2018; 9: 1607. doi: 10.3389/fmicb.2018.01607.Kasai C., Sugimoto K., Moritani I., Tanaka J., Oya Y., Inoue H. et al.Comparison of human gut microbiota in control subjects and patients with colorectal carcinoma in adenoma: Terminal restriction fragment length polymorphism and next-generation sequencing analyses. Oncol Rep. 2016; 35(1): 325-33. doi: 10.3892/or.2015.4398.Kasai C., Sugimoto K., Moritani I., Tanaka J., Oya Y., Inoue H. et al.Comparison of human gut microbiota in control subjects and patients with colorectal carcinoma in adenoma: Terminal restriction fragment length polymorphism and next-generation sequencing analyses. Oncol Rep. 2016; 35(1): 325-33. doi: 10.3892/or.2015.4398.Matera G., Muto V., Vinci M., Zicca E., Abdollahi-Roodsaz S., van de Veerdonk F. L. et al. Receptor recognition of and immune intracellular pathways for Veillonella parvula lipopolysaccharide. Clin Vaccine Immunol. 2009; 16(12): 1804-9. doi: 10.1128/CVI.00310-09.Matera G., Muto V., Vinci M., Zicca E., Abdollahi-Roodsaz S., van de Veerdonk F. L. et al. Receptor recognition of and immune intracellular pathways for Veillonella parvula lipopolysaccharide. Clin Vaccine Immunol. 2009; 16(12): 1804-9. doi: 10.1128/CVI.00310-09.De Cruz P., Kang S., Wagner J., Buckley M., Sim WH., Prideaux L. et al. Association between specific mucosa-associated microbiota in Crohn’s disease at the time of resection and subsequent disease recurrence: a pilot study. J Gastroenterol Hepatol. 2015; 30(2): 268-78. doi: 10.1111/jgh.12694.De Cruz P., Kang S., Wagner J., Buckley M., Sim WH., Prideaux L. et al. Association between specific mucosa-associated microbiota in Crohn’s disease at the time of resection and subsequent disease recurrence: a pilot study. J Gastroenterol Hepatol. 2015; 30(2): 268-78. doi: 10.1111/jgh.12694.Bongaerts G.P., Schreurs B. W., Lunel F. V., Lemmens J. A., Pruszczynski M., Merkx M. A. Was isolation of Veillonella from spinal osteomyelitis possible due to poor tissue perfusion? Med Hypotheses. 2004; 63(4): 659-61. doi: 10.1016/j.mehy.2004.02.052.Bongaerts G.P., Schreurs B. W., Lunel F. V., Lemmens J. A., Pruszczynski M., Merkx M. A. Was isolation of Veillonella from spinal osteomyelitis possible due to poor tissue perfusion? Med Hypotheses. 2004; 63(4): 659-61. doi: 10.1016/j.mehy.2004.02.052.Rovery C., Etienne A., Foucault C., Berger P., Brouqui P. Veillonella montpellierensis endocarditis. Emerg Infect Dis. 2005; 11(7): 1112-4. doi: 10.3201/eid1107.041361.Rovery C., Etienne A., Foucault C., Berger P., Brouqui P. Veillonella montpellierensis endocarditis. Emerg Infect Dis. 2005; 11(7): 1112-4. doi: 10.3201/eid1107.041361.Wei Y., Li Y., Yan L., Sun C., Miao Q., Wang Q. et al. Alterations of gut microbiome in autoimmune hepatitis. Gut. 2020; 69(3): 569-577. doi: 10.1136/gutjnl-2018-317836.Wei Y., Li Y., Yan L., Sun C., Miao Q., Wang Q. et al. Alterations of gut microbiome in autoimmune hepatitis. Gut. 2020; 69(3): 569-577. doi: 10.1136/gutjnl-2018-317836.Downes J., Hooper S. J., Wilson M. J., Wade W. G. Prevotella histicola sp. nov., isolated from the human oral cavity.Int J Syst Evol Microbiol. 2008; 58(Pt 8): 1788-91. doi: 10.1099/ijs.0.65656-0.Downes J., Hooper S. J., Wilson M. J., Wade W. G. Prevotella histicola sp. nov., isolated from the human oral cavity.Int J Syst Evol Microbiol. 2008; 58(Pt 8): 1788-91. doi: 10.1099/ijs.0.65656-0.Balakrishnan B., Luckey D., Bodhke R., Chen J., Marietta E., Jeraldo P. et al. Prevotella histicola Protects From Arthritis by Expansion of Allobaculum and Augmenting Butyrate Production in Humanized Mice. Front Immunol. 2021; 12: 609644. doi: 10.3389/fimmu.2021.609644.Balakrishnan B., Luckey D., Bodhke R., Chen J., Marietta E., Jeraldo P. et al. Prevotella histicola Protects From Arthritis by Expansion of Allobaculum and Augmenting Butyrate Production in Humanized Mice. Front Immunol. 2021; 12: 609644. doi: 10.3389/fimmu.2021.609644.Mangalam A.K., Murray J. Microbial monotherapy with Prevotella histicola for patients with multiple sclerosis. Expert Rev Neurother. 2019; 19(1): 45-53. doi: 10.1080/14737175.2019.1555473.Mangalam A.K., Murray J. Microbial monotherapy with Prevotella histicola for patients with multiple sclerosis. Expert Rev Neurother. 2019; 19(1): 45-53. doi: 10.1080/14737175.2019.1555473.Shahi S.K., Jensen S. N., Murra A. C., Tang N., Guo H., Gibson-Corley K.N. et al. Human Commensal Prevotella histicola Ameliorates Disease as Effectively as Interferon-Beta in the Experimental Autoimmune Encephalomyelitis. Front Immunol. 2020; 11: 578648. doi: 10.3389/fimmu.2020.578648.Shahi S.K., Jensen S. N., Murra A. C., Tang N., Guo H., Gibson-Corley K.N. et al. Human Commensal Prevotella histicola Ameliorates Disease as Effectively as Interferon-Beta in the Experimental Autoimmune Encephalomyelitis. Front Immunol. 2020; 11: 578648. doi: 10.3389/fimmu.2020.578648.Liu C.Y., Su W. B., Guo L. B., Zhang Y. W. Cloning, expression, and characterization of a novel heparinase I from Bacteroides eggerthii. Prep Biochem Biotechnol. 2020; 50(5): 477-485. doi: 10.1080/10826068.2019.1709977.Liu C.Y., Su W. B., Guo L. B., Zhang Y. W. Cloning, expression, and characterization of a novel heparinase I from Bacteroides eggerthii. Prep Biochem Biotechnol. 2020; 50(5): 477-485. doi: 10.1080/10826068.2019.1709977.Kmezik C., Krska D., Mazurkewich S., Larsbrink J. Characterization of a novel multidomain CE15-GH8 enzyme encoded by a polysaccharide utilization locus in the human gut bacterium Bacteroides eggerthii. Sci Rep. 2021; 11(1): 17662. doi: 10.1038/s41598-021-96659-z.Kmezik C., Krska D., Mazurkewich S., Larsbrink J. Characterization of a novel multidomain CE15-GH8 enzyme encoded by a polysaccharide utilization locus in the human gut bacterium Bacteroides eggerthii. Sci Rep. 2021; 11(1): 17662. doi: 10.1038/s41598-021-96659-z.Petersen A.B., Christensen I. A., Rønne M. E., Stender E. G.P., Teze D., Svensson B. et al.1H,13C,15N resonance assignment of the enzyme KdgF from Bacteroides eggerthii. Biomol NMR Assign. 2022; 16(2): 343-347. doi: 10.1007/s12104-022-10102-6.Petersen A.B., Christensen I. A., Rønne M. E., Stender E. G.P., Teze D., Svensson B. et al.1H,13C,15N resonance assignment of the enzyme KdgF from Bacteroides eggerthii. Biomol NMR Assign. 2022; 16(2): 343-347. doi: 10.1007/s12104-022-10102-6.Domingo M.C., Yansouni C., Gaudreau C., Lamothe F., Lévesque S., Tremblay C. et al. Cloacibacillus sp., a Potential Human Pathogen Associated with Bacteremia in Quebec and New Brunswick. Clin Microbiol. 2015; 53(10): 3380-3. doi: 10.1128/JCM.01137-15.Domingo M.C., Yansouni C., Gaudreau C., Lamothe F., Lévesque S., Tremblay C. et al. Cloacibacillus sp., a Potential Human Pathogen Associated with Bacteremia in Quebec and New Brunswick. Clin Microbiol. 2015; 53(10): 3380-3. doi: 10.1128/JCM.01137-15.Puón-Peláez X.D., McEwan N.R., Gómez-Soto J.G., Álvarez-Martínez R.C., Olvera-Ramírez A. M. Metataxonomic and Histopathological Study of Rabbit Epizootic Enteropathy in Mexico. Animals (Basel). 2020; 10(6): 936. doi: 10.3390/ani10060936.Puón-Peláez X.D., McEwan N.R., Gómez-Soto J.G., Álvarez-Martínez R.C., Olvera-Ramírez A. M. Metataxonomic and Histopathological Study of Rabbit Epizootic Enteropathy in Mexico. Animals (Basel). 2020; 10(6): 936. doi: 10.3390/ani10060936.

The authors declare that there are no conflicts of interest present.